Company profile

RemeGen Co., Ltd.

688331 · SSE / HKEX

Public Market Listing

688331SSE / HKEX

SSE / HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for RemeGen Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
0Approved
4Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Disitamab Vedotin
Phase 3
HER2Antibody–drug conjugate
Non-Small Cell Lung CancerHR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
RC148
Phase 3
PD-1 + VEGFSmall molecule
Non-Small Cell Lung Cancer
RC28-E
Phase 3
VEGF-A / FGF-2 (dual blockade)Protein / enzyme therapeutic
Age-Related Macular Degeneration
Telitacicept
Phase 3
BAFF / APRILProtein / enzyme therapeutic
Systemic Lupus Erythematosus
RC108
Phase 2
METAntibody–drug conjugate
Non-Small Cell Lung Cancer
RC198
Phase 1
Undisclosed / early pipelineSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.